Beyond the Headlines: What the Lancet Study on Chile’s Warning Labels Really Demonstrates
A new study published in The Lancet has rapidly become one of the most-cited pieces of evidence supporting Chile’s warning-label policy (FLAL). Around the world, it is already being presented as proof that warning labels reduce childhood obesity.
But does the study really support this conclusion?
Our latest Competere analysis reviews the paper in detail, separating the scientific evidence from the public narrative. The objective is not to dismiss the research, but to understand what it actually demonstrates, what it does not, and what questions policymakers should still be asking before treating the Chilean model as a policy success.
Read the full Competere analysis here
Key Takeaways
- The study evaluates a multi-component regulatory package, not warning labels in isolation.
- The public narrative surrounding the paper is considerably stronger than the evidence it actually provides.
- The observed effect is statistically significant but quantitatively modest, affecting a specific population of children aged 4–6 years.
- The estimated reduction in energy intake is only 16.4 kcal per person per day, raising important questions about proportionality and practical relevance.
- The study does not demonstrate long-term effects on obesity, diabetes, cardiovascular disease, or overall population health.
- No statistically significant effects are observed in rural areas, raising questions about equity, transferability, and effectiveness among vulnerable populations.
- The analysis does not evaluate costs, unintended consequences, health literacy, behavioural autonomy, or alternative prevention strategies such as education, physical activity, and personalised prevention.
- Statistical significance should not be confused with policy significance. A statistically detectable effect does not automatically justify broad public policy.
Why This Analysis Matters
The Lancet paper is an important scientific contribution because it is among the first attempts to move beyond market outcomes—such as product reformulation or purchasing behaviour—and evaluate a health outcome.
That alone makes it worthy of careful attention.
READ PAGANINI NON RIPETE 315: WE DO NOT NEED A CLASSIFICATION FOR THE UPFS
However, our review concludes that the evidence is substantially more limited than the way the study has been communicated through media, advocacy networks, and public debate.
The paper does not demonstrate that warning labels alone reduce childhood obesity. Instead, it examines a broader regulatory package combining front-of-pack warning labels, marketing restrictions, and school food policies. The authors themselves acknowledge that it is impossible to isolate the contribution of each measure.
Moreover, the reported effect is modest, context-specific, and measured over a relatively short period. The study does not provide evidence of sustained reductions in obesity, diabetes, cardiovascular disease, or other long-term health outcomes.
Perhaps most importantly, it does not answer the questions that ultimately matter for policymaking.
Are the observed benefits proportionate to the economic, social, and regulatory costs?
Do these measures work equally well across different populations?
ARE YOU IN A SIMULATION? READ PAGANINI NON RIPETE 314
Could education, health literacy, physical activity, personalised prevention, and digital technologies achieve better results with fewer unintended consequences?
These questions remain open.
From Scientific Evidence to Public Policy
Scientific studies help us understand whether an intervention may produce measurable effects.
Public policy requires something more.
It requires proportionality.
It requires a cost-benefit assessment.
FOOD IS STRATEGIC INFRASTRUCTURE: READ MY TALK AT THE ASSICA GENERAL ASSEMBLY IN ROME
It requires evidence that people’s health actually improves.
The Competere analysis argues that these broader policy considerations are largely absent from the current discussion surrounding the Chilean model.
Rather than closing the debate on warning labels, the new Lancet paper should encourage a more rigorous one.
Read the Full Competere Analysis
The complete Competere Policy Analysis provides a detailed review of the study’s methodology, findings, limitations, and policy implications.
If the discussion on warning labels is to move beyond headlines and ideology, it must begin with a careful reading of the evidence.
Read the full Competere analysis here
